{"id":305070,"date":"2026-09-07T00:00:00","date_gmt":"2026-09-07T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2024-biopharma-non-small-cell-lung-cancer-landscape-forecast-disease-landscape-forecast-2\/"},"modified":"2026-09-14T05:01:26","modified_gmt":"2026-09-14T05:01:26","slug":"dlsfon0007-2026-biopharma-non-small-cell-lung-cancer-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0007-2026-biopharma-non-small-cell-lung-cancer-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Non-Small-Cell Lung Cancer &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The multibillion-dollar <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> therapy market is highly dynamic, with more than 40 targeted drugs approved, but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck &#038; Co.) dominate the field, but many are facing near-term patent expiry. Subcutaneous formulations of these agents offer not only convenience advantages but also an extension to the lifecycle of the drug. Therapeutics addressing driver mutations such as <em><abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr> <\/em>and <em><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/em> also play a crucial role in the <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> market, which is significantly biomarker-segmented. These segments will see increasingly fierce competition, especially in the first-line metastatic setting, where the interplay of efficacy and tolerability attributes will influence market share. Expected new market entrants will further drive dynamism in the <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXP133646606 BCX0 round-bullets\">\n<li>How will the recent and expected new market entrants shape treatment algorithms in the various settings and stages (I-<span class=\"abbreviation-guard\">IV<\/span>) of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>Which therapies will dominate the commercially lucrative first-line metastatic <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> setting?<\/li>\n<li>What are the most promising pipeline products, and what will be their likely uptake and patient share in <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>What are the <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> therapy market&#8217;s key drivers and constraints, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Geographies:<\/strong> United States, France, germany, Italy, Spain, United Kingdom, Japan.<\/li>\n<li><strong>Primary research:<\/strong> Country-specific interviews with thought-leading medical oncologists. Survey data collected for this and other Clarivate research.<\/li>\n<li><strong>Epidemiology:<\/strong> Diagnosed incidence of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> by country, histology, stage, and line of therapy, segmented into relevant drug-treatable populations.<\/li>\n<li><strong>Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> therapies through 2035, segmented by brands \/ generics and epidemiological subpopulations<\/li>\n<li><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies.<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-305070","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-solid-tumors","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}